HIMSS, CHIME announce 2012 CIO of the year

Luke Gale | | Health Exec | Digital Transformation

James Turnbull, MBA, CIO at University of Utah Health Care (UUHC) in Salt Lake City, was selected by the College of Healthcare Information Management Executives (CHIME) and the Health Information and Management Systems Society (HIMSS) to receive the 2012 CIO of the Year award. 

A CHIME member since 1993, Turnbull was previously employed as CIO at Children's Hospital in Denver and as CIO at Sarasota Memorial Hospital. Under his leadership, both UUHC and Children's Hospital received "most wired" awards and Children's Hospital was recognized by market researcher KLAS as the most integrated children's hospital. 

An award will be presented to Turnbull March 5 at the annual HIMSS conference in New Orleans. 

Luke Gale

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.